Clinuvel Pharmaceuticals (CUV AU) has sole marketed drug, Scenesse, approved in the U.S. and Europe for the treatment of a rare skin disorder that causes extreme sensitivity to light.
Scenesse revenue jumped 65% y/y in H1FY22, due to increasing patient demand. With the re-opening of expert centers, treatment has largely normalized in Europe.
Clinuvel has rich pipeline, to develop pharmaceutical products to treat a range of indications and non-prescription healthcare solutions to individuals in the wider population.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.